Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02028325 · ClinicalTrials.gov registry record · Phase 4
Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions
A Phase 4 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 136
- Enrollment target
NCT02028325 is a Phase 4 study that was terminated before completion, run by Indiana University. The registered enrollment target is 136 participants.
The verdict
NCT02028325, a Phase 4 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of using Fluorescein Sodium and the Yellow 560 microscope to aid in treatment of intracranial tumors and vascular lesions.
Interventions
- DRUG Fluorescein Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02028325
The ClinicalTrials.gov registry entry for NCT02028325 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluorescein Sodium is the first listed.
NCT02028325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02028325 about?
NCT02028325 is a clinical study titled "Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions". The purpose of this study is to evaluate the effectiveness of using Fluorescein Sodium and the Yellow 560 microscope to aid in treatment of intracranial tumors and vascular lesions.
What is the current status of trial NCT02028325?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 136 participants. The study started on 2013-12. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02028325?
The interventions under investigation include: Fluorescein Sodium (DRUG).
Who is sponsoring clinical trial NCT02028325?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.